Beaman GM, Galatà G, Teik KW, et al. A homozygous missense variant in *CHRM3* associated with familial urinary bladder disease. Clin Genet. 2019;96:515--520. 10.1111/cge.13631 31441039

**Peer Review** The peer review history for this article is available at <https://publons.com/publon/10.1111/cge.13631>.

**Funding information** Academy of Medical Sciences; Manchester NIHR BRC, Grant/Award Number: IS‐BRC‐1215‐20007; Medical Research Council, Grant/Award Number: MR/L002744/1; Newlife Foundation for Disabled Children, Grant/Award Numbers: 15‐15/03, 15‐16/06; NIHR Academic Lecturer scheme

1. INTRODUCTION {#cge13631-sec-0001}
===============

Urinary bladder abnormalities not only devastate children\'s health but also cause major disruption to the lives of families. The last decade has witnessed discoveries of gene variants in specific classes of congenital urinary bladder abnormalities, including prune belly,[1](#cge13631-bib-0001){ref-type="ref"}, [2](#cge13631-bib-0002){ref-type="ref"} urofacial[3](#cge13631-bib-0003){ref-type="ref"}, [4](#cge13631-bib-0004){ref-type="ref"}, [5](#cge13631-bib-0005){ref-type="ref"}, [6](#cge13631-bib-0006){ref-type="ref"} and visceral myopathy (megacystis‐microcolon‐intestinal‐hypoperistalsis)[7](#cge13631-bib-0007){ref-type="ref"}, [8](#cge13631-bib-0008){ref-type="ref"}, [9](#cge13631-bib-0009){ref-type="ref"}, [10](#cge13631-bib-0010){ref-type="ref"}, [11](#cge13631-bib-0011){ref-type="ref"} syndromes. In some of these cases, the associated genes encode proteins involved in the intracellular contractile apparatus of bladder smooth muscle. These genes comprise *MYH11* encoding myosin light chain kinase,[8](#cge13631-bib-0008){ref-type="ref"} *ACTA2* encoding α‐smooth muscle actin,[2](#cge13631-bib-0002){ref-type="ref"} and *ACTG2* encoding γ2‐smooth muscle actin,[7](#cge13631-bib-0007){ref-type="ref"} all muscle cytoskeletal proteins; and *MYLK* that codes for myosin light chain kinase, required for myosin activation.[9](#cge13631-bib-0009){ref-type="ref"} In other cases, genes that have been associated with bladder malformations code for proteins implicated in the neuro‐muscular circuits required for bladder voiding.[12](#cge13631-bib-0012){ref-type="ref"}, [13](#cge13631-bib-0013){ref-type="ref"} As examples, *HPSE2* codes for heparanase 2 and *LRIG2* codes for leucine rich repeats and immunoglobulin‐like domains 2, proteins detected in foetal bladder nerves; variants of these genes are implicated in urofacial syndrome.[5](#cge13631-bib-0005){ref-type="ref"}, [6](#cge13631-bib-0006){ref-type="ref"}, [14](#cge13631-bib-0014){ref-type="ref"}

Also in the neuro‐muscular category is *CHRM3* that encodes M3, the key acetylcholine receptor expressed by detrusor smooth muscle cells that is required for parasympathetic‐driven detrusor contraction and bladder emptying.[2](#cge13631-bib-0002){ref-type="ref"}, [13](#cge13631-bib-0013){ref-type="ref"}, [15](#cge13631-bib-0015){ref-type="ref"} Weber et al[1](#cge13631-bib-0001){ref-type="ref"} reported a family with six brothers who were born to consanguineous Turkish parents. They had congenital prune belly‐like syndrome characterised by hypocontractile bladders that failed to empty completely. Each affected boy available for testing harboured a homozygous frameshift variant of *CHRM3*, predicted to lead to a truncated protein and thus explaining the hypocontractile bladder phenotype. The affected brothers also had impaired pupillary constriction to light, a notable feature given that the M3 acetylcholine receptor is expressed in pupillary sphincter muscle, mediating its contractions.[15](#cge13631-bib-0015){ref-type="ref"}, [16](#cge13631-bib-0016){ref-type="ref"} Furthermore, male mice that carry homozygous targeted loss of function mutations of *Chrm3* have a similar syndrome affecting the bladder and the eye.[17](#cge13631-bib-0017){ref-type="ref"} In this report, we present a second family carrying a homozygous variant in *CHRM3* associated with familial urinary bladder disease.

2. METHODS {#cge13631-sec-0002}
==========

The family (Figure [1](#cge13631-fig-0001){ref-type="fig"}A) was recruited as part of a nationally and internationally sourced cohort of 20 unrelated families with phenotypes overlapping urinary bladder voiding dysfunction of unknown cause. Independent of this case, we identified a single affected individual with a pathogenic de novo *ACTG2* c.769C \> T, Arg257Cys variant. Institutional ethical review and approval (UK; University of Manchester \[06138\] and National Research Ethics Service North West, Greater Manchester Central ethics committee \[06/Q1406/52 and 11/NW/0021\]) was granted, and informed consent was provided.

![Identification of *CHRM3* mutation in Malaysian family. A, Family pedigree of Malaysian family, who were screened by Sanger sequencing for the c.352G \> A variant, indicated by \*. Filled in symbols represent affected individuals. B, Schematic diagram showing that the variant alters a residue within the second transmembrane domain of the M3 acetylcholine receptor and segregated with disease in the affected family. The diagram also depicts the frameshift variant identified by Weber et al.[1](#cge13631-bib-0001){ref-type="ref"} C, Predicted second transmembrane domain, the identified mutation alters a conserved glycine (G) residue which is highly conserved. D ‐ F, Genomic sequence chromatograms. ‐ D, I:1, I:2, II:1, II:3 Heterozygous for variant (unaffected carriers) (E) II:4, II:6 Homozygous for variant (affected) (F) II:5 Wild type (unaffected) \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](CGE-96-515-g001){#cge13631-fig-0001}

A targeted enrichment to sequence all the exons of RefSeq transcripts of 13 genes previously associated with urinary bladder voiding abnormalities was designed (*HPSE2*, *LRIG2*, *CHRM3*, *ACTG2*, *MYH11*, *ACTA2*, *DSTYK*, *HNF1B*, *ROBO2*, *TBX18*, *TNXB*, *TSHZ3*, *UPK3A*). Using manufacturers\' protocols, DNA samples from peripheral blood were enriched by an Agilent SureSelect Custom Design target‐enrichment kit (Agilent, Santa Clara, California) and sequenced with the Illumina MiSeq (Illumina, San Diego, California). Subsequent sequence alignment, variant calling, annotation and filtering were performed as reported previously.[18](#cge13631-bib-0018){ref-type="ref"} Variants of interest were confirmed using Sanger sequencing following standard procedures.

An 840 bp fragment of *CHRM3* was amplified from patient or reference genomic DNA by polymerase chain reaction (PCR) and cloned into the SK3 plasmid (a derivative of the pSpliceExpress mini‐gene splice reporter vector, a gift from Stefan Stamm, Addgene \#32485) using the NEbuilder method (New England Biolabs). Successfully cloned constructs were transformed into competent bacteria and candidate colonies were cultured then vector DNA isolated. Sequences of mini‐gene vector constructs were verified by Sanger sequencing (performed by Eurofins Genomics).

HEK293 cells were cultured overnight to 40% to 50% confluency in Dulbecco\'s modified Eagle\'s medium high‐glucose, DMEM (Sigma), supplemented with 10% foetal bovine serum (Sigma) in six well tissue culture‐treated plates at 37°C with 5% CO~2~. Cells were transiently transfected with 1 μg of mini‐gene vector using Lipofectamine LTX (Thermofisher Scientific) and the manufacturer\'s recommended protocol. Following 20 hours incubation at 37°C with 5% CO~2~, RNA was extracted using the ReliaPrep RNA extraction kit (Promega) which included a DNase digestion step. An equal amount of RNA for each sample was converted to cDNA using Supercript IV (ThermoFisher Scientific). cDNA was amplified using Phusion polymerase and specific mini‐gene primers (Forward 5′‐GCACCTTTGTGGTTCTCACT‐3′, Reverse 5′‐GGGCCTAGTTGCAGTAGTTCT‐3′). Finally, PCR products were separated on an agarose gel (1%) supplemented with SafeView nucleic acid stain (NBS Biologicals) and visualised under a blue‐light transilluminator. Where appropriate, bands of interest were extracted and purified using QIAquick gel extraction kit (Qiagen) and sequenced by Sanger sequencing (Eurofins Genomics) to confirm their identity.

3. RESULTS {#cge13631-sec-0003}
==========

The proband (II:4) was found to have a novel homozygous missense variant in *CHRM3*, c.352G \> A; p.(Gly118Arg) NM_000740.3. This variant was not present in a database of exome and genome sequence data from \>120 000 healthy individuals (GnomAD, <http://gnomad.broadinstitute.org>) and is predicted by in silico tools of variant function to be probably damaging by Polyphen‐2, deleterious by SIFT and disease causing by MutationTaster. The variant was not found to influence splicing of the *CHRM3* pre‐mRNA in a mini‐gene splicing assay. The glycine residue at position 118 in the protein is conserved to zebra fish indicating its evolutionary importance. The variant alters a residue within the second transmembrane domain of the M3 acetylcholine receptor and segregated with disease in the affected family (Figure [1](#cge13631-fig-0001){ref-type="fig"}B‐F) such that the two affected members who were available for testing were homozygous for the variant. No other putative pathogenic variants were identified in the sequence panel testing undertaken in this family.

II:4 was born at full term to consanguineous Malaysian parents, antenatal scans were not performed. From birth, she was noted to have a distended abdomen and a poor urinary stream and from the second month, she was established on clean intermittent bladder catheterization. She had undergone numerous radiological investigations in the first months after birth. Ultrasonography revealed two kidneys of normal lengths but with mild to moderate hydronephrosis and dilated upper ureter on the left side; the bladder was distended with a slightly thickened and irregular wall. A micturating cystourethrogram found no evidence of spina bifida, urethral obstruction or vesicoureteral reflux but the bladder was enlarged and irregular, with a large residual volume. A Tc99m‐diethylenetriaminepentacetate (DTPA) isotope scan showed symmetrical function with tracer hold‐up in the left renal pelvis with wash‐out following intravenous furosemide diuretic administration. Magnetic resonance imaging of the lumbo‐sacral spine was normal. Urodynamics undertaken when she was 3 years showed a hypocontractile bladder with a normal capacity of 152 mL and at 11 years showed a functionally obstructed bladder with a normal capacity of 400 mL. During the first 3 years of life, she had one or two urinary tract infections each year and then no further infections until she was a teenager. She suffers from constipation. She left school in early childhood due to poor attainment but there is no evidence of specific intellectual disability. Assessment at 15 years old revealed that her pupils were 5 mm in diameter, with no constriction to light, and her urinary bladder was palpable (Table [1](#cge13631-tbl-0001){ref-type="table"}).

###### 

Clinical features in individuals with disorders associated with CHRM3

                                              Family 1 (Weber et al 2011)[1](#cge13631-bib-0001){ref-type="ref"}   F2 (Pomper et al 2011)[19](#cge13631-bib-0019){ref-type="ref"} [a](#cge13631-note-0003){ref-type="fn"}   F3 (This report)                                                                                                          
  ------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------ ------- ------- ---------------------- --------------------------- ----------- ----------------------- -----------------------
  Status                                      Deceased                                                             Alive                                                                                                    Alive              Alive   Alive   Alive                  Alive                       Deceased    Alive                   Alive
  Abdominal wall distension                   \+                                                                   −                                                                                                        −                  \+      −       −                      −                           −           \+                      −
  Incomplete bladder emptying after voiding   u/k                                                                  \+                                                                                                       \+                 \+      \+      \+                     \+                          u/k         \+                      \+
  Other urinary tract phenotype               Renal failure urosepsis                                              −                                                                                                        −                  −       −       Bladder diverticulae   Urinary stones, urosepsis   Urosepsis                           
  Pupillary restriction to light              \+                                                                   \+                                                                                                       \+                 \+      \+      \+                     \+                          \+          \+                      \+
  Dry mouth                                   \+                                                                   \+                                                                                                       \+                 \+      \+      \+                     −                           u/k         −                       −
  Other phenotype                             −                                                                    −                                                                                                        −                  −       −       −                      Lean habitus                −           Constipation, mild ID   Constipation, mild ID

Abbreviations: NR, not reported; u/k, unknown, +, feature present, −, feature absent.

No *CHRM3* variants identified.

She has a clinically unaffected brother (II:1) who was heterozygous for the variant. Her other older brother (II:2) had died at the age of 6 years after a short unspecified illness. He had a history of multiple urinary tract infections and a vesicostomy had been fashioned at 8 months of age. Further details of the individual are not available. Tissue was not available for genetic testing. Her older clinically unaffected sister (II:3) was also heterozygous for the variant.

The index case has two younger siblings, both female. One (II.5) is alive and well with no urinary tract symptoms, and wild type for the variant. The other (II:6) had an antenatal ultrasound scan which revealed a distended bladder with left‐sided hydronephrosis. She was born at term and underwent several radiological investigations in the first 4 months of life. Ultrasonography showed a normal spine, two kidneys of normal length, bilateral hydronephrosis, right hydroureter and bladder wall thickening. Tc99m‐DTPA scanning showed that the right kidney contributed only 35% of total function and there was progressive tracer accumulation in the pelvicalyceal system that washed out adequately into the dilated ureter. A micturating cystourethrogram showed an irregular bladder outline, in keeping with a neurogenic bladder but there was no vesicoureteral reflux. She was treated with intermittent catheterisation. In the first 4 years of life, she had one to two urinary tract infections per year, despite antibiotic prophylaxis. On examination aged 6 years, she was noted to have a palpable urinary bladder. An ultrasound examination showed two kidneys of normal length and echogenicity. She suffered from intermittent constipation and at 9 years old requires special educational support for mild intellectual disability. She did not have a formal neurocognitive evaluation. Her pupils were 5 mm in diameter that constricted minimally to light.

4. DISCUSSION {#cge13631-sec-0004}
=============

Prune belly syndrome due to biallelic variants in *CHRM3* is an ultra‐rare disorder. No subsequent reports have been published since the original family in 2011.[1](#cge13631-bib-0001){ref-type="ref"} This report represents a second family with bladder disease in individuals carrying a homozygous *CHRM3* variant. In common with the family reported by Weber et al,[1](#cge13631-bib-0001){ref-type="ref"} the affected members in the kindred presented with dysfunctional voiding associated with hypocontractile bladders; moreover, in both families, the disease was present at birth. The current report also emphasises that the *CHRM3*‐associated disease is not sex‐limited because, while all clinically affected siblings in the Weber et al [1](#cge13631-bib-0001){ref-type="ref"} report were male, the disease in the family presented here affected two girls and most likely also their brother who died in childhood. In contrast, in mice carrying a homozygous targeted *Chrm3* mutation, the overdistended bladder phenotype only manifests in males.[17](#cge13631-bib-0017){ref-type="ref"} This observation might be in part explained by the fact that the male urethra is longer than the female counterpart, so higher intra‐vesical pressures are needed to expel urine. In fact, the male phenotype may be more severe in humans, with early deaths only observed in males in this report and that of Weber et al.[1](#cge13631-bib-0001){ref-type="ref"} The precise mechanism whereby males are more severely affected is as yet unclear but may be related to the anatomical differences, including urethral length. In both the current family and the one reported by Weber et al,[1](#cge13631-bib-0001){ref-type="ref"} affected members had impairment of pupillary constriction in response to light. Indeed, the presence of dysfunction of both the bladder and the eye is fully consistent with the hypothesis that M3 function was absent, or severely impaired, in both families. While Weber et al[1](#cge13631-bib-0001){ref-type="ref"} described a homozygous frameshift variant, the current family harboured a homozygous missense variant (Figure [1](#cge13631-fig-0001){ref-type="fig"}B). Of interest, Pomper et al[19](#cge13631-bib-0019){ref-type="ref"} described a patient who had impaired micturition and pupillary constriction and also had decreased levels of M3 protein in bladder tissue; however, *CHRM3* sequencing and copy number analyses were normal. We speculate that this patient may have harboured non‐coding variants that affect transcription of *CHRM3*.

*CHRM3* comprises five exons although only one of these is coding. Therefore, the frameshift variant identified in the original report[1](#cge13631-bib-0001){ref-type="ref"} is likely to escape nonsense‐mediated decay and a truncated protein will likely be formed. The missense variant reported here has no effect on splicing in an in vitro system and although it is predicted to result in reduced function, the specific mechanism requires further elucidation.

Unfortunately, *CHRM3* genotyping data representing a healthy Malaysian population is not available either publically or could be generated through this study and so it is possible that p.(Gly118Arg) represents a rare polymorphism in this population. Other in silico evidence of conservation and predicted pathogenicity and segregation with the phenotype support the causality of this variant. Although the missense variant is absent in GnomAD, it is present as a somatic variant in a number of databases of genotypes in cancer tissues.

Heterozygous copy number variants at chromosome 1q43, the locus for *CHRM3*, have been reported associated with developmental problems. A 473 kb deletion, removing only *CHRM3*, was identified in a young male with autistic features.[20](#cge13631-bib-0020){ref-type="ref"} Parental samples were not available to determine whether this was de novo. Furthermore, a larger de novo deletion encompassing three genes, including *CHRM3* was present in a male with learning disability, cryptorchidism, short stature and alopecia.[21](#cge13631-bib-0021){ref-type="ref"} A 763 kb duplication encompassing *CHRM3* alone was detected in a male with intellectual and developmental delay, autistic behaviour, short stature, and hand anomalies.[22](#cge13631-bib-0022){ref-type="ref"} It is important to note that the parents in the original report and in our family with heterozygous *CHRM3* variants are clinically normal. Therefore, these data indicate that dosage effects of *CHRM3* may be associated with a clinical developmental phenotype, distinct from the bladder and pupillary phenotype in individuals with biallelic coding variants.

*CHRM3* is overexpressed in bladders of adults with benign prostatic hypertrophy,[20](#cge13631-bib-0020){ref-type="ref"} most likely a compensatory response to anatomic bladder outflow obstruction. The M3 acetylcholine receptor is in fact more widely expressed than in the detrusor and ciliary muscles.

Although dilated pupils are present in all affected individuals reported to date with biallelic *CHRM3* variants indicating that this is a core feature of the phenotype, the association of bladder dysfunction with mydriasis is not exclusive to individuals with *CHRM3* variants. Of note individuals with biallelic pathogenic variants in *MYL9* have mydriasis as part of megacystis microcolon intestinal hypoperistalsis phenotype.[11](#cge13631-bib-0011){ref-type="ref"} The similarity in the bladder‐eye phenotype in the two families would indicate that the missense variant results in a loss of function comparable to that predicted by the frameshift variant identified by Weber et al.[1](#cge13631-bib-0001){ref-type="ref"} It will be important through murine and cellular studies to undertake functional studies to determine the mechanism of action of the reported disease‐associated variants. The report of this second family provides independent evidence that biallelic variants in *CHRM3* result in severe bladder voiding dysfunction which on the basis of the families described to date is associated with mydriasis and is more severe, resulting in early lethality, in males.
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